Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01924793 · ClinicalTrials.gov registry record · Phase 2
An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection
A Phase 2 study, sponsored by Ansun Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT01924793 is a Phase 2 study that has completed, run by Ansun Biopharma. The registered enrollment target is 23 participants.
The verdict
NCT01924793, a Phase 2 study, has completed, sponsored by Ansun Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This protocol will seek to enroll up to 60 immunocompromised subjects diagnosed with parainfluenza infection. All subjects will have additional PK and Immunogenicity blood samples collected.
Interventions
- DRUG DAS181-F02 Dry Powder in Bulk
- DRUG DAS181-F02 Nebulized Formulation Inhaled Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2013-08 |
| Est. Completion | 2017-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01924793
The ClinicalTrials.gov registry entry for NCT01924793 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ansun Biopharma, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DAS181-F02 Dry Powder in Bulk is the first listed.
NCT01924793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01924793 about?
NCT01924793 is a clinical study titled "An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection". This protocol will seek to enroll up to 60 immunocompromised subjects diagnosed with parainfluenza infection. All subjects will have additional PK and Immunogenicity blood samples collected.
What is the current status of trial NCT01924793?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2013-08. Estimated completion is 2017-05.
What interventions are being tested in trial NCT01924793?
The interventions under investigation include: DAS181-F02 Dry Powder in Bulk (DRUG), DAS181-F02 Nebulized Formulation Inhaled Dose (DRUG).
Who is sponsoring clinical trial NCT01924793?
This trial is sponsored by Ansun Biopharma, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.